Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2020 > Vol 1, №2 (2020) > Generalized sarcoidosis and severe thrombocytopenic purpura: clinical observation and literature review

Generalized sarcoidosis and severe thrombocytopenic purpura: clinical observation and literature review

L.A. Ponomareva , L.A. Panchenko , A.B. Ponomarev , E.N. Popova , Yu.V. Putincev

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Sarcoidosis is a disease of an unknown etiology and is characterized by a wide range of clinical manifestations due to granulomatous damage of the lungs and other organs. Hematologic disorders in sarcoidosis are represented by different variants of pancytopenia, while autoimmune thrombocytopenic purpura is rare. Hemorrhagic syndrome with critical thrombocytopenia in blood of a patient with systemic sarcoidosis (damage to the lungs, nervous system, skin) coincided with an episode of a viral infection with symptoms of COVID-19 and the detection of an increased titer of antibodies to SARS-CoV-2 in the blood. In our paper we described the clinical features of the disease, medical treatment. The issues 
of managing patients with sarcoidosis during a pandemic time are discussed.

Key words: COVID-19, sarcoidosis, autoimmune thrombocytopenic purpura.

About the Author

L.A. Ponomareva 1 , L.A. Panchenko 2 , A.B. Ponomarev 1 , E.N. Popova 1 , Yu.V. Putincev 3

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

2 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

3 Consultative and Diagnostic Center of the private healthcare institution «Central clinical hospital «RZD-Medicine», Moscow, Russia

References

1. Baughman RP, Teirstein AS, Judson MA et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10 pt. 1): 1885–9.
2. Kayar Y, Kayar NB, Unver N, Ekinci I. Sarcoidosis Presenting with Severe Thrombocytopenia. Int J Respir Pulm Med 2016; 3: 056. DOI: 10.23937/2378-3516/1410056
3. Ponomareva L.A., Gurova D.V., Popova E.N. et al. Metotreksat – indutsirovannoe porazhenie legkikh u bol'noi revmatoidnym artritom: klinicheskoe nabliudenie i obzor literatury. Terapevticheskii arkhiv. 2021; 3 (in Russian).
4. Larner AJ, Dollery CT, Cox TM et al. Life threatening thrombocytopenia in sarcoidosis. BMJ 1990; 300 (6720): 317–9. DOI: 10.1136/bmj.300.6720.317
5. Moulis G, Palmaro A, Montastruc JL et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014; 124 (22): 3308–15. DOI: 10.1182/blood-2014-05-578336. PMID: 25305203.
6. Fordice J, Katras T, Jackson RE et al. Massive splenomegaly in sarcoidosis. South Med J 1992; 85 (7): 775–8. DOI: 10.1097/00007611-199207000-00028. PMID: 1631702.
7. Mahévas M, Chiche L, Uzunhan Y et al. Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20 patients. Medicine (Baltimore) 2011; 90 (4): 269–78. DOI: 10.1097/MD.0b013e31822618b3
8. Mahévas M, Le Page L, Salle V et al. Thrombocytopenia in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (3): 229–35. PMID: 18038923.
9. Judson MA, Costabel U, Drent M et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 19–27.
10. Lawrence HJ, Greenberg BR. Autoimmune thrombocytopenia in sarcoidosis. Am J Med 1985; 79 (6): 761–4. DOI: 10.1016/0002-9343(85)90528-5. PMID: 4073111.
11. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol 2020; 99 (6): 1205–8. DOI: 10.1007/s00277-020-04019-0
12. Crouser ED, Lozanski G, Fox CC et al. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-alpha therapy. Chest 2010; 137: 1432–5.
13. Nagaharu K, Masuya M, Kawakami K, Katayama N. Successful Management of Immune Thrombocytopenia Presenting with Lethal Alveolar Hemorrhage. Case Rep Hematol 2019; 2019: 5170282. DOI: 10.1155/2019/5170282
14. Judson MA, Baughman RP, Teirstein AS et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (1): 75–86.

For citation:Ponomareva L.A., Panchenko L.A., Ponomarev A.B., Popova E.N., Putincev Yu.V. Generalized sarcoidosis and severe thrombocytopenic purpura: clinical observation and literature review. Clinical review for general practice. 2020; 2: 6–10. DOI: 10.47407/kr2020.1.2.00011


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru